Germany - Drugs

Description

This notice does not concern the award of a public contract within the meaning of the Public Procurement Coordination Directive (2014/24/EU) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The procedural designation "open procedure" (Section IV.1.1) used in the text of this announcement is due to the requirements of the announcement form. Neither this nor the use of the "TED" medium is associated with any submission to procurement law regulations, the application of which is not mandatory by virtue of the law or procurement regulations. This is a framework agreement with an option to join, which relates to various active ingredients.
The subject of the agreement are drugs containing the active ingredient adalimumab. The contract covers drugs containing the active ingredient combination beclometasone, formoterol and glycopyrronium. The contract covers medicinal products containing the active ingredient biperiden in a sustained-release oral dosage form. The contract covers medicinal products containing the active ingredient combination brinzolamide and timolol. The subject of the Agreement are medicinal products containing the active ingredient clomipramine. The subject of the Agreement are medicinal products containing the active ingredient desfesoterodine. The Contractual Products are medicinal products containing the active ingredient dexamethasone in the form of eye drops. The subject of the contract are medicinal products containing the active ingredient enoxaparin sodium in the strengths 60 mg, 80 mg and 100 mg; except N1 and 24 pieces. The subject of the Agreement are medicinal products containing the active ingredient fentanyl in a nasal dosage form. The subject of the contract are medicinal products containing the active ingredient follitropin alfa. The subject of the Agreement are medicinal products containing the active ingredient Ganirelix. The subject of the Agreement are medicinal products containing the active ingredient ivermectin. The subject of the Agreement are drugs containing the active ingredient lanreotide. The Contractual Products are medicinal products containing the active ingredient latanoprost in the dosage form of single-dose pipettes. The subject of the Agreement are medicinal products containing the active ingredient lenograstim. The subject of the Agreement are medicinal products containing the active ingredient leuprorelin in a sustained release dosage form (except implants). The subject of the Agreement are medicinal products containing the active ingredient levothyroxine. The subject of the Agreement are medicinal products containing the active ingredient Lipegfilgrastim. The subject of the Agreement are medicinal products containing the active ingredient meloxicam. The contract covers medicinal products containing the active ingredient combination olodaterol and tiotropium. The subject of the Agreement are medicinal products containing the active ingredient palonosetron in a solid oral dosage form. The subject of the Agreement are medicinal products containing the active ingredient pirfenidone. The subject of the agreement are medicinal products containing the active ingredient raltegravir. The subject of the Agreement are medicinal products containing the active ingredient sevelamer hydrochloride. The subject of the Agreement are medicinal products containing the active ingredient somatropin. The Contractual Products are medicinal products containing the active substance tapentadol. The subject of the Agreement are medicinal products containing the active ingredient tiotropium. The Contractual Products are medicinal products containing the active ingredient trastuzumab with an active strength of 420 mg. The subject of the agreement are medicinal products containing the active ingredient vildagliptin. The subject of the agreement are medicinal products containing the active ingredient combination vildagliptin and metformin. The contract covers medicinal products containing the active ingredient zoledronic acid at 5 mg.

Opportunity closing date

01 November 2024

Value of contract

£0-100k